ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Accounts Payable
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Accounts Payable of -$1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$765.00K, a 179.27% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.21M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.67M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.68M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for fiscal 2025 was $421.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for fiscal 2024 was -$4.02M, a 978.60% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for fiscal 2023 was $458.00K, a 89.84% decline from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in accounts payable for fiscal 2022 was $4.51M, a 36.96% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$765.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.98M 10-Q · filed 2026-08-06 | -$3.64M derived: sum of 3 quarters · filed 2026-08-06 | -$1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.21M 10-Q · filed 2026-05-08 | -$2.88M derived: sum of 2 quarters · filed 2026-05-08 | -$1.20M derived: sum of 3 quarters · filed 2026-05-08 | -$233.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.00K derived: sum of 2 quarters · filed 2026-03-09 | $977.00K derived: sum of 3 quarters · filed 2026-08-06 | $421.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.65M derived: sum of 2 quarters · filed 2026-08-06 | $2.09M 10-Q · filed 2025-11-07 | -$1.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $965.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $409.00K 10-Q · filed 2026-08-06 | -$2.98M derived: sum of 3 quarters · filed 2026-08-06 | -$3.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$556.00K 10-Q · filed 2026-05-08 | -$3.94M derived: sum of 2 quarters · filed 2026-05-08 | -$4.14M derived: sum of 3 quarters · filed 2026-05-08 | -$2.25M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$3.58M derived: sum of 2 quarters · filed 2026-03-09 | -$1.70M derived: sum of 3 quarters · filed 2026-03-09 | -$4.02M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.69M derived: sum of 2 quarters · filed 2025-11-07 | -$637.00K 10-Q · filed 2025-11-07 | -$5.12M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$443.00K 10-Q · filed 2025-08-12 | -$4.93M derived: sum of 3 quarters · filed 2026-03-09 | $3.96M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$2.33M 10-Q · filed 2025-05-08 | -$6.81M derived: sum of 2 quarters · filed 2026-03-09 | $2.08M derived: sum of 3 quarters · filed 2026-03-09 | -$3.63M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.40M derived: sum of 2 quarters · filed 2026-03-09 | -$1.31M derived: sum of 3 quarters · filed 2026-03-09 | $458.00K 10-K · filed 2026-03-09 |
| 2023-09-30 | $8.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.17M derived: sum of 2 quarters · filed 2024-11-07 | $4.94M 10-Q · filed 2024-11-07 | $7.40M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$5.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.94M 10-Q · filed 2024-08-12 | -$1.49M derived: sum of 3 quarters · filed 2025-03-06 | -$4.55M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $1.77M 10-Q · filed 2024-05-09 | $4.22M derived: sum of 2 quarters · filed 2025-03-06 | $1.16M derived: sum of 3 quarters · filed 2025-03-06 | $4.72M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$610.00K derived: sum of 2 quarters · filed 2025-03-06 | $2.95M derived: sum of 3 quarters · filed 2025-03-06 | $4.51M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $499.00K derived: sum of 2 quarters · filed 2023-11-13 | $2.05M 10-Q · filed 2023-11-13 | $1.72M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.12M 10-Q · filed 2023-08-10 | $4.79M derived: sum of 3 quarters · filed 2024-03-07 | $2.60M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-11 | $1.22M derived: sum of 2 quarters · filed 2024-03-07 | -$959.00K derived: sum of 3 quarters · filed 2024-03-07 | -$2.50M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$2.51M derived: sum of 2 quarters · filed 2024-03-07 | -$4.06M derived: sum of 3 quarters · filed 2024-03-07 | $3.29M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$3.73M derived: sum of 2 quarters · filed 2022-11-08 | $3.62M 10-Q · filed 2022-11-08 | $2.20M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $5.80M 10-Q · filed 2022-08-08 | $4.38M derived: sum of 3 quarters · filed 2023-03-09 | $4.06M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $7.35M 10-Q · filed 2022-05-09 | $5.92M derived: sum of 2 quarters · filed 2023-03-09 | $5.61M derived: sum of 3 quarters · filed 2023-03-09 | $5.36M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.74M derived: sum of 2 quarters · filed 2023-03-09 | -$1.98M derived: sum of 3 quarters · filed 2023-03-09 | -$3.74M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$562.00K derived: sum of 2 quarters · filed 2021-11-12 | -$2.32M 10-Q · filed 2021-11-12 | $744.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$2.00M 10-Q · filed 2021-08-12 | $1.06M derived: sum of 3 quarters · filed 2022-02-28 | $497.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$1.76M 10-Q · filed 2021-05-17 | $1.31M derived: sum of 2 quarters · filed 2022-02-28 | $739.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.50M derived: sum of 2 quarters · filed 2022-02-28 | $2.98M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$567.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$91.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $476.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | -$269.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |